ଆନିଫ୍ରୋଲୁମାବ

ଆନିଫ୍ରୋଲୁମାବ
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Interferon α/β receptor
Clinical data
Trade names	Saphnelo
Synonyms	MEDI-546, anifrolumab-fnia
AHFS/Drugs.com	monograph
data	US DailyMed: Anifrolumab;
Pregnancy; category	AU: C ; ;
Routes of; administration	Intravenous
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; US: ℞-only ; EU: Rx-only ;
Chemical and physical data
Formula	C6444H9964N1712O2018S44
Molar mass	୧,୪୫,୧୧୯.୨0 g·mol−1

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Anifrolumab

ଆନିଫ୍ରୋଲୁମାବ (ଇଂରାଜୀ ଭାଷାରେ Anifrolumab), ସଫନେଲୋ ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ସିସ୍ଟମିକ୍ ଲୁପସ୍ ଏରିଦେମାଟୋସସ୍ (SLE) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୫] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ମଧ୍ୟମରୁ ଗମ୍ଭୀର ଧରଣର ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ଯାହା ସାଧାରଣ ଚିକିତ୍ସାଦ୍ୱାରା ନିୟନ୍ତ୍ରିତ ହୋଇପାରେ ନାହିଁ ।^[୫] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୫]

ସବୁଠାରୁ ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟା ହେଉଛି ଉର୍ଦ୍ଧ୍ୱ ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ ଏବଂ ବ୍ରୋଙ୍କାଇଟିସ୍ ହୋଇପାରେ ।^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ହର୍ପିସ ଜୋସ୍ଟରଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୪] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ ।^[୫] ଏହା ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ଯାହା ଇଣ୍ଟରଫେରନ୍ ରିସେପ୍ଟର ପ୍ରକାର୧ ସ‌ହିତ ସଂଯୁକ୍ତ ହୋଇ ଟାଇପ୧ ଇଣ୍ଟରଫେରନ୍ ଗୁଡ଼ିକର କାର୍ଯ୍ୟକଳାପକୁ ଅବରୋଧ କରେ ।^[୪]

୨୦୨୧ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୨୨ରେ ୟୁରୋପରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଆନିଫ୍ରୋଲୁମାବ ଅନୁମୋଦିତ ହୋଇଥିଲା ^[୫] ^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୨ ସୁଦ୍ଧା ଏହାର ଏକ ମାତ୍ରାର ମୂଲ୍ୟ ପ୍ରାୟ ୫୦୦୦ ଡଲାର ଥିଲା ।^[୬] ୨୦୨୨ ସୁଦ୍ଧା ବ୍ରିଟେନରେ ଏହା ବ୍ୟବସାୟିକ ଭାବରେ ଉପଲବ୍ଧ ହୋଇନାହିଁ ।^[୭]

ଆଧାର[ସମ୍ପାଦନା]

↑ ^୧.୦ ^୧.୧ "Saphnelo APMDS". Therapeutic Goods Administration (TGA). 12 April 2022. Archived from the original on 19 September 2022. Retrieved 24 April 2022.
↑ "Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]". Health Canada. 24 January 2022. Archived from the original on 29 May 2022. Retrieved 28 May 2022.
↑ "Summary Basis of Decision (SBD) for Saphnelo". Health Canada. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Saphnelo EPAR". European Medicines Agency. 16 December 2021. Archived from the original on 12 April 2022. Retrieved 11 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ "Saphnelo- anifrolumab injection, solution". DailyMed. Archived from the original on 12 August 2021. Retrieved 11 August 2021.
↑ "Saphnelo Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2022.
↑ "Anifrolumab". SPS - Specialist Pharmacy Service. 23 December 2015. Archived from the original on 31 July 2017. Retrieved 29 October 2022.

[Saphnelo_APMDS-1] ୧.୦ ^୧.୧ "Saphnelo APMDS". Therapeutic Goods Administration (TGA). 12 April 2022. Archived from the original on 19 September 2022. Retrieved 24 April 2022.

[2] "Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]". Health Canada. 24 January 2022. Archived from the original on 29 May 2022. Retrieved 28 May 2022.

[3] "Summary Basis of Decision (SBD) for Saphnelo". Health Canada. Archived from the original on 29 May 2022. Retrieved 29 May 2022.

[EPAR2022-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Saphnelo EPAR". European Medicines Agency. 16 December 2021. Archived from the original on 12 April 2022. Retrieved 11 April 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ "Saphnelo- anifrolumab injection, solution". DailyMed. Archived from the original on 12 August 2021. Retrieved 11 August 2021.

[6] "Saphnelo Prices, Coupons, Copay & Patient Assistance". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2022.

[7] "Anifrolumab". SPS - Specialist Pharmacy Service. 23 December 2015. Archived from the original on 31 July 2017. Retrieved 29 October 2022.

[୧]

[୨]

[୩]

[୫]

[୪]

[୬]

[୭]